Norepinephrine News and Research

RSS

Disturbance of serotonin can lead to sudden infant death syndrome

University of Chicago researchers and colleagues have found strong support that a disturbance of a specific neurochemical can lead to sudden infant death syndrome, the primary cause of death before age 1 in the United States.

13 Mar 2006

Alcoholism, smoking and genetics among Plains American Indians

Alcoholism and smoking have a high rate of co-occurrence in the general population. Yet little is known about the co-morbidity of alcoholism and smoking among American Indians.

23 Feb 2006

Botox finds a use in cancer treatment

The cosmetic treatment Botox may have a new use as an adjuvant to cancer therapy, providing an open door for chemotherapy and radiation treatments, according to a study published in the Feb. 15 issue of Clinical Cancer Research.

17 Feb 2006

Mechanism of torpor - hibernation-like state

If doctors could put people in hibernation and pull them out at will, scientists think they could minimize damage from strokes, help recipients' bodies accept transplanted organs, perhaps even enable astronauts to travel in suspended animation until reaching distant destinations.

7 Feb 2006

Study may provide new hope for cancer patients

New study by Mount Sinai researchers may lead to improved stem cell therapies for patients with compromised immune systems due to intensive cancer therapy or autoimmune disease. The study is published in this week's issue of Cell.

27 Jan 2006

Run, skip, hop, jump or just walk to lift those blues

Researchers at the University of Texas at Austin say a single 30-minute walk on a treadmill can give a temporary emotional lift to patients diagnosed with major depressive disorder.

26 Jan 2006

Acetazolamide improves central sleep apnea in heart failure

Since sleep apnea is associated with heart failure, patients who take a single dose of acetazolamide - a mild diuretic and respiratory stimulant - before going to bed exhibit less sleep apnea, improved blood oxygen levels and fewer daytime symptoms of sleepiness.

16 Jan 2006

Depressed heart patients skip medications

Recent studies conducted at the San Francisco VA Medical Center suggest two possible mechanisms for the widely recognized link between depression and adverse outcomes in patients with coronary heart disease: lack of adherence to medication regimens and increased levels of norepinephrine, a stress hormone.

2 Dec 2005

Noise can increase risk of heart attack

New research published online in European's leading cardiology journal, European Heart Journal, links exposure to chronic noise with an increased risk of heart attack.

28 Nov 2005

GRK2 protein - potential drug target for heart failure

A protein that plays an important regulatory role in heart failure in the heart also exerts powerful effects on the adrenal gland, Jefferson Medical College researchers have found. The protein, GRK2, is a potential drug target for heart failure.

28 Nov 2005

Beta-blockers may help deal with stress

An experience as simple as watching graphically violent or emotional scenes in a movie can induce enough stress to interfere with problem-solving abilities, new research at Ohio State University Medical Center suggests.

20 Nov 2005

Animal-assisted therapy beneficial

When it comes to health care, "going to the dogs" is a good thing, according to new research reported at the American Heart Association's Scientific Sessions 2005.

16 Nov 2005

New York-Presbyterian Hospital offers Vagus Nerve Stimulation (VNS) Therapy

New York-Presbyterian Hospital/Columbia University Medical Center is the first in the greater New York City-area to offer Vagus Nerve Stimulation (VNS) Therapy as a long-term treatment specifically approved by the FDA for treatment-resistant depression (TRD).

7 Nov 2005

Enzyme in the blood that could be a potential marker for heart failure

A team of scientists led by Walter Koch, Ph.D., director of the Center for Translational Medicine in the Department of Medicine in Jefferson Medical College of Thomas Jefferson University in Philadelphia, previously showed that an enzyme called GRK2 or beta-adrenergic kinase (ßARK1) is critically important in heart function.

22 Aug 2005

Older-style antidepressants, as well as anticonvulsant drugs, can help ease the disabling pain caused by nerve tissue damage

For many years antidepressants, which are believed to work by dampening pain signals, have been the first-line drugs for neuropathic pain. "It is usual to start with an antidepressant like amitriptyline, and if this fails then try an anticonvulsant," says Phil Wiffen, a researcher at Churchill Hospital in Oxford, England. "The results of these meta-analyses suggest this is probably still the best approach to take."

19 Jul 2005

Creative thinking: try lying down

Keep that pen and paper by the bed: new research by an Australian National University (ANU) PhD graduate suggests it may be that our most creative thoughts come when we’re lying down.

10 May 2005

EU calls for tougher warnings on antidepressants for kids

A committee of experts in Europe are calling for strong warnings to be placed on two classes of antidepressants, informing doctors and parents of the risk they could pose to children and adolescents.

25 Apr 2005

Brain-injury rehabilitation depends on acetylcholine circuitry

The ability of the brain to recover from such injury as stroke or trauma depends on a particular circuitry of neurons that "talk" to one another using the brain chemical acetylcholine, researchers led by James Conner and Mark Tuszynski in the Neural repair Group at UCSD have discovered.

20 Apr 2005

Sudden emotional stress can result in severe but reversible heart muscle weakness

Shocking news, such as learning of the unexpected death of a loved one, has been known to cause catastrophic events, such as a heart attack.

10 Feb 2005

European approval of Cymbalta/Xeristar for treatment of major depressive episodes

Eli Lilly and Company and Boehringer Ingelheim announced today that Cymbalta/Xeristar (duloxetine hydrochloride)(+) has been granted marketing authorization by the European Commission for the treatment of major depressive episodes.

5 Jan 2005